The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors

Abstract

Current cancer therapies are often associated with treatment failure and reduced patients’ survival due to drug resistance. There are various mechanisms involved in the acquisition of cancer drug resistance, including the selection of advantageous mutations, overexpression of transporter proteins and epigenetic alterations. In this context, epigenetic alterations refer to chromatin-mediated regulation of gene expression that results in heritable changes in the cellular phenotype. There is an ever-growing body of evidence suggesting that epigenetic mechanisms play an important role in bringing about drug resistance in cancer cells. While the relationship between chemotherapy and epigenetics has been widely discussed, emerging evidence indicates that specific epigenetic effectors are also crucial for the development of resistance to tyrosine kinase inhibitors (TKIs). One particular gene that encodes the histone lysine demethylase KDM5A is overexpressed in several cancers. In breast cancer tissues, cells with KDM5A gene amplification were found to be more resistant to erlotinib, an inhibitor of the tyrosine kinase epidermal growth factor receptor (EGFR), when compared to cells without the same amplification. KDM5A was also shown to mediate resistance to a second EGFR inhibitor called gefitinib, in EGFR-mutant lung cancer cell lines. This evidence indicates that KDM5A could activate alternative survival pathways involved in overcoming EGFR inhibition. In line with these results, another histone demethylase (i.e., KDM1A) promotes liver cancer cells’ resistance to the TKI sorafenib. Current evidence provides a suitable rationale to consider the use of specific KDMs inhibitors to sensitize cells to tyrosine kinase targeted therapies and thus, presents an opportunity to prevent the further development of drug resistance. This review discusses the involvement of histone lysine demethylases in the development of resistance to TKI and highlights the importance to develop new cancer treatment regimens to counteract this phenomenon.

Keywords

Epigenetics / drug resistance / cancer

References

[1] Arora A.Role of tyrosine kinase inhibitors in cancer therapy..J Pharmacol Exp Ther2005;315:971-9

[2] Hollenberg MD.Tyrosine kinase-mediated signal transduction pathways and the actions of polypeptide growth factors and G-protein-coupled agonists in smooth muscle..Mol Cell Biochem1995;149-150:77-85

[3] Anafi M,Zehavi A,Levitzki A.Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate..Blood1993;82:3524-9

[4] Meydan N,Dadi H,Arpaia E.Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor..Nature1996;379:645-8

[5] Oxnard GR,Nishino M,Lindeman NI.Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions..J Thorac Oncol2013;8:179-84 PMCID:PMC3549533

[6] Arcila ME,Chaft JE,Lau C.EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics..Mol Cancer Ther2013;12:220-9 PMCID:PMC3714231

[7] Yang JC,Geater SL,Mok TS.Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6..Lancet Oncol2015;16:830-8

[8] Sequist LV,Dias-Santagata D,Turke AB.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors..Sci Transl Med2011;3:75ra26 PMCID:PMC3132801

[9] Campo M,Gainor JF,Temel JS.Acquired resistance to first-line afatinib and the challenges of prearranged progression biopsies..J Thorac Oncol2016;11:2022-6

[10] Yu HA,Rekhtman N,Zakowski MF.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers..Clin Cancer Res2013;19:2240-7 PMCID:PMC3630270

[11] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm..Nat Rev Cancer2013;13:714-26

[12] Debatin KM.Death receptors in chemotherapy and cancer..Oncogene2004;23:2950-66

[13] Lowe SW,Evan G.Intrinsic tumour suppression..Nature2004;432:307-15

[14] Druker BJ,Buchdunger E,Segal GM.Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells..Nat Med1996;2:561-6

[15] Taylor ST,Dive C.Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and bax by tumor microenvironmental factors..J Natl Cancer Inst2000;92:18-23

[16] Goldberg AD,Bernstein E.Epigenetics: a landscape takes dhape..Cell2007;128:635-8

[17] Lemmon MA.Cell signaling by receptor tyrosine kinases..Cell2010;141:1117-34 PMCID:PMC2914105

[18] Paul MK.Tyrosine kinase - role and significance in cancer..Int J Med Sci2004;1:101-15 PMCID:PMC1074718

[19] Lisovsky M,Zhang X,Sanchez-Williams G.Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax..Blood1996;88:3987-97

[20] Testa U.The impact of FLT3 mutations on the development of acute myeloid leukemias..Leuk Res Treatment2013;2013:275760 PMCID:PMC3725705

[21] Bertram JS.The molecular biology of cancer..Mol Aspects Med2000;21:167-223

[22] Vogelstein B,Velculescu VE,Diaz LA Jr.Cancer genome landscapes..Science2013;339:1546-58 PMCID:PMC3749880

[23] Carraway KL.EGF receptor activation by heterologous mechanisms..Cancer Cell2002;1:405-6

[24] Groffen J,Heisterkamp N,Bartram CR.Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22..Cell1984;36:93-9

[25] Singh AB.Autocrine, paracrine and juxtacrine signaling by EGFR ligands..Cell Signal2005;17:1183-93

[26] Kentsis A,Rice KL,Rodig SJ.Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia..Nat Med2012;18:1118-22 PMCID:PMC3438345

[27] Krystal GW,Organ CP.Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor..Cancer Res1996;56:370-6

[28] O’Brien SG,Larson RA,Baccarani M.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia..N Engl J Med2003;348:994-1004

[29] Kris MG,Herbst RS,Prager D.A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2)..Proc Am Soc Clin Oncol2002;21:

[30] Fukuoka M,Giaccone G,Nakagawa K.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer..J Clin Oncol2003;21:2237-46

[31] Hidalgo M,Nemunaitis J,Hammond LA.Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies..J Clin Oncol2001;19:3267-79

[32] Moore MJ,Kamel-Reid S,Tu D.The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on national cancer institute of canada clinical trials group trial study PA.3..J Clin Oncol2007;25:4521

[33] Moore MJ,Hamm J,Hecht JR.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group..J Clin Oncol2007;25:1960-6

[34] de Claro RA,Verdun N,Chiu HJ.CCR perspectives in drug approval FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia CME staff planners’ disclosures acknowledgment of financial or other support..Clin Cancer Res2015;21:3586-90

[35] Castillo JJ,Advani R.Ibrutinib in waldenström macroglobulinemia: latest evidence and clinical experience..Ther Adv Hematol2016;7:179-86 PMCID:PMC4959643

[36] Sun L,Shirazian S,Miller T.Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase..J Med Chem2003;46:1116-9

[37] Shah NP.Mechanisms of resistance to STI571 in philadelphia chromosome-associated leukemias..Oncogene2003;22:7389-95

[38] Druker BJ,O’Brien SG,Kantarjian H.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia..N Engl J Med2006;355:2408-17

[39] Shah NP,Lee FY,Norris D.Overriding imatinib resistance with a novel ABL kinase inhibitor..Science2004;305:399-401

[40] Lombardo LJ,Chen P,Barrish JC.Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual src/abl kinase inhibitor with potent antitumor activity in preclinical assays..J Med Chem2004;47:6658-61

[41] Grüllich C.Cabozantinib: a met, ret, and VEGFR2 tyrosine kinase inhibitor..Recent Results Cancer Res2014;201:207-14

[42] U.S. Food and Drug Administration. FDA grants regular approval to cabometyx for first-line treatment of advanced renal cell carcinoma. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589842. [Last assessed on 27 Mar 2019]

[43] Zhou Y,Zou H,Chen X.The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells..Sci Rep2015;5:8629 PMCID:PMC4342569

[44] Morabito A,Falasconi F,Del Giudice A.Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions..Oncologist2009;14:378-90

[45] Lugowska I,Kozak K.Trametinib: a MEK inhibitor for management of metastatic melanoma..Onco Targets Ther2015;8:2251-9 PMCID:PMC4556032

[46] Verstovsek S,Mesa RA,Cortes-Franco J.Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis..N Engl J Med2010;363:1117-27 PMCID:PMC5187954

[47] Verstovsek S,Gotlib J,Gupta V.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis..N Engl J Med2012;366:799-807 PMCID:PMC4822164

[48] Harrison C,Al-Ali HK,Waltzman R.JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis..N Engl J Med2012;366:787-98

[49] Johnson TW,Bailey S,Burke BJ.Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and board-spectrum potency against ALK-resistant mutations..J Med Chem2014;57:4720-44

[50] Animal Cell Technology Industrial Platform. Monoclonal antibodies approved by the EMA and FDA for therapeutic use (status 2017). Available from: http://www.actip.org/products/monoclonal-antibodies-approved-by-the-ema-and-fda-for-therapeutic-use. [Last assessed on 27 Mar 2019]

[51] Liu MZ,He FZ,Zhou HH.Epigenetic perspectives on cancer chemotherapy response..Pharmacogenomics2014;15:699-715

[52] Strauss J.Using epigenetic therapy to overcome chemotherapy resistance..Anticancer Res2016;36:1-4 PMCID:PMC6388403

[53] Bannister AJ.Regulation of chromatin by histone modifications..Cell Res2011;21:381-95 PMCID:PMC3193420

[54] Kharkar VJ,Gupta S.LSD2/KDM1B/AOF1 and human cancer pathways: a literature review..Cancer Stud Ther2016;1:1-5

[55] Greer EL.Histone methylation: a dynamic mark in health, disease and inheritance..Nat Rev Genet2012;13:343-57 PMCID:PMC4073795

[56] Suzuki T,Tange S.Roles of histone methyl-modifying enzymes in development and progression of cancer..Cancer Sci2013;104:795-800

[57] Rotili D.Targeting histone demethylases: a new avenue for the fight against cancer..Genes Cancer2011;2:663-79 PMCID:PMC3174264

[58] Tian X,Liu HM,Blair CA.Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention..Curr Cancer Drug Targets2013;10:558-79 PMCID:PMC3703250

[59] Thinnes CC,Kawamura A,Schofield CJ.Targeting histone lysine demethylases - progress, challenges, and the future..Biochim Biophys Acta2014;1839:1416-32 PMCID:PMC4316176

[60] Fu X,Yu B.Advances toward LSD1 inhibitors for cancer therapy..Future Med Chem2017;9:1227-42

[61] Kang MK,Park NH.Epigenetic gene regulation by histone demethylases: emerging role in oncogenesis and inflammation..Oral Dis2017;23:709-20 PMCID:PMC5493521

[62] Oh S.Histone demethylase JMJD5 is essential for embryonic development..Biochem Biophys Res Commun2012;420:61-5

[63] Strobl-Mazzulla PH,Bronner-Fraser M.Histone demethylase JmjD2A regulates neural crest specification..Dev Celll2010;19:460-8 PMCID:PMC2939072

[64] Black JC,Van Rechem C,Ladd B.KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors..Cell2013;154:541-55 PMCID:PMC3832053

[65] Young LC.The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression..Biochem Cell Biol2013;91:369-77

[66] Young LC,Hendzel MJ.Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-Irradiation..J Biol Chem2013;288:21376-88 PMCID:PMC3774405

[67] Lu Y,Oeck S.Hypoxia promotes resistance to EGFR inhibition in NSCLC cells via the histone demethylases, LSD1 and PLU-1..Mol Cancer Res2018;16:1458-69 PMCID:PMC6170700

[68] Oral histone deacetylase inhibitor 4SC-202 in patients with advanced hematologic malignancies (TOPAS). Available from: https://clinicaltrials.gov/ct2/show/NCT01344707. [Last assessed on 27 Mar 2019]

[69] European Medicines Agency. Clinical trials register - search for ORY-1001. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=ORY-1001. [Last assessed on 27 Mar 2019]

[70] U.S. National Library of Medicine. Study of sensitization of Non-M3 AML blasts to ATRA by epigenetic treatment with tranylcypromine (TCP) (TRANSATRA). Available from: https://clinicaltrials.gov/ct2/show/NCT02717884. [Last assessed on 27 Mar 2019]

[71] U.S. National Library of Medicine. Phase 1 study of TCP-ATRA for adult patients with AML and MDS (TCP-ATRA). Available from: https://clinicaltrials.gov/ct2/show/NCT02273102. [Last assessed on 27 Mar 2019]

[72] Huang M,Geng J,Wang T.Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma..Cancer Lett2017;398:12-21

[73] Hou J,Dombkowski A,Holowatyj A.Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer..Am J Transl Res2012;4:247-56 PMCID:PMC3426386

[74] Gale M,Cao J,Gareiss P.Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance..Oncotarget2016;7:39931-44 PMCID:PMC5129982

[75] Fahim Golestaneh A,Schwager C,Macher-Goeppinger S.Abstract 3254: discovery of histone demethylase KDM5C inactivation as a novel mechanism for tumors resistant to VEGF RTKi via genome-wide in-vivo RNAi..Cancer Res2016;76:3254

[76] Zimmermannova O, Kanderova V, Kuzilkova D, Lund-Johansen F, Doktorova E, et al. Multilevel molecular profiling to dissect resistance to tyrosine kinase inhibitors in TEL/ABL positive acute lymphoblastic leukemia. Available from: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/kongresy/po-kongresu/databaze-tuzemskych-onkologickych-konferencnich-abstrakt/multilevel-molecular-profiling-to-dissect-resistance-to-tyrosine-kinase-inhibito/. [Last assessed on 27 Mar 2019]

[77] Sharma SV,Li B,Takahashi F.A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations..Cell2010;141:69-80 PMCID:PMC2851638

[78] Shibue T.EMT, CSCs, and drug resistance: the mechanistic link and clinical implications..Nat Rev Clin Oncol2017;14:611-29 PMCID:PMC5720366

[79] Mohammad HP,Kamat CD,Federowicz KE.A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC..Cancer Cell2015;28:57-69

[80] Liang Y,Narayanan A,Kristie TM.Inhibition of the histone demethylase LSD1 blocks α-herpesvirus lytic replication and reactivation from latency..Nat Med2009;15:1312-7 PMCID:PMC2783573

[81] Fiskus W,Shah B,Devaraj SGT.Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells..Leukemia2014;28:2155-64 PMCID:PMC4739780

[82] Kusserow A,Sturm C,Lentfer J.Unexpected complexity of the Wnt gene family in a sea anemone..Nature2005;433:156-60